Home Cart Sign in  
Chemical Structure| 109613-93-6 Chemical Structure| 109613-93-6

Structure of 109613-93-6

Chemical Structure| 109613-93-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 109613-93-6 ]

CAS No. :109613-93-6
Formula : C7H9NO2
M.W : 139.15
SMILES Code : COC1=C(OC)C=NC=C1
MDL No. :MFCD04037427
InChI Key :OSSPPRKJEQZZQH-UHFFFAOYSA-N
Pubchem ID :820376

Safety of [ 109613-93-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 109613-93-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 37.22
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

31.35 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.77
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.79
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.1
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.13
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.32
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.97

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.51
Solubility 4.28 mg/ml ; 0.0307 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.03
Solubility 13.0 mg/ml ; 0.0935 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.25
Solubility 0.779 mg/ml ; 0.0056 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.59 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.68

Application In Synthesis of [ 109613-93-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 109613-93-6 ]

[ 109613-93-6 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 186581-53-3 ]
  • [ 153199-54-3 ]
  • [ 109613-93-6 ]
  • 2
  • [ 2591-86-8 ]
  • [ 109613-93-6 ]
  • 3,4-dimethoxy-2-formylpyridine [ No CAS ]
  • 3
  • [ 109613-93-6 ]
  • [ 75-77-4 ]
  • 3,4-dimethoxy-2-(trimethylsilyl)pyridine [ No CAS ]
  • 4
  • [ 109613-93-6 ]
  • [ 100-52-7 ]
  • 1-(3,4-dimethoxy-2-pyridyl)phenylmethanol [ No CAS ]
  • 5
  • [ 109613-93-6 ]
  • [ 75-07-0 ]
  • 1-(3,4-dimethoxy-2-pyridyl)ethanol [ No CAS ]
  • 6
  • [ 109613-93-6 ]
  • [ 68-12-2 ]
  • 3,4-dimethoxy-2-formylpyridine [ No CAS ]
  • 7
  • [ 109613-93-6 ]
  • [ 109-94-4 ]
  • 3,4-dimethoxy-2-formylpyridine [ No CAS ]
  • 8
  • [ 109613-93-6 ]
  • [ 74-88-4 ]
  • [ 107512-35-6 ]
  • 9
  • [ 109613-93-6 ]
  • [ 104819-52-5 ]
  • 11
  • [ 109613-93-6 ]
  • 2-deuterio-3,4-dimethoxypyridine [ No CAS ]
  • 12
  • [ 101664-59-9 ]
  • [ 109613-93-6 ]
  • [ 101664-55-5 ]
  • 13
  • [ 109-04-6 ]
  • [ 109613-93-6 ]
  • [ 173289-69-5 ]
  • 14
  • [ 109613-93-6 ]
  • [ 220089-79-2 ]
  • [ 220089-80-5 ]
  • 15
  • [ 109613-93-6 ]
  • [ 124-38-9 ]
  • [ 220437-83-2 ]
  • 16
  • [ 186581-53-3 ]
  • 3-methoxy-pyridin-4-ol trihydrate [ No CAS ]
  • [ 109613-93-6 ]
  • 17
  • [ 109613-93-6 ]
  • methyl-(3-hydroxy-4-methoxypicolinyl)serine [ No CAS ]
  • 18
  • [ 109613-93-6 ]
  • [ 220437-84-3 ]
  • 19
  • [ 109613-93-6 ]
  • [ 188048-45-5 ]
  • 20
  • [ 109613-93-6 ]
  • [ 220089-83-8 ]
  • 21
  • [ 109613-93-6 ]
  • [ 220089-77-0 ]
  • 22
  • [ 109613-93-6 ]
  • [ 220089-84-9 ]
  • 23
  • [ 109613-93-6 ]
  • [ 220089-82-7 ]
  • 24
  • [ 109613-93-6 ]
  • 3,4-dimethoxy-5-methyl-2,2'-bipyridine [ No CAS ]
  • 25
  • [ 109613-93-6 ]
  • [ 173289-63-9 ]
  • 26
  • [ 109613-93-6 ]
  • [ 173289-58-2 ]
  • 27
  • [ 109613-93-6 ]
  • [ 173289-57-1 ]
  • 28
  • [ 109613-93-6 ]
  • [ 173289-68-4 ]
  • 29
  • [ 109613-93-6 ]
  • 6-deuterio-3,4-dimethoxy-2,2'-bipyridine [ No CAS ]
  • 30
  • [ 109613-93-6 ]
  • 5-deuterio-3,4-dimethoxy-2,2'-bipyridine [ No CAS ]
  • 31
  • [ 109613-93-6 ]
  • 5,6-dibromo-3,4-dimethoxy-2,2'-bipyridine [ No CAS ]
  • 32
  • [ 109613-93-6 ]
  • 5,6-diiodo-3,4-dimethoxy-2,2'-bipyridine [ No CAS ]
  • 33
  • [ 109613-93-6 ]
  • 5-iodo-6-formyl-3,4-dimethoxy-2,2'-bipyridine [ No CAS ]
  • 34
  • [ 109613-93-6 ]
  • caerulomycin C [ No CAS ]
  • 35
  • [ 109613-93-6 ]
  • 3,4-dimethoxy-5-(trimethylsilyl)-2,2'-bipyridine [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 109613-93-6 ]

Ethers

Chemical Structure| 7295-76-3

A274716 [7295-76-3]

3-Methoxypyridine

Similarity: 0.84

Chemical Structure| 620-08-6

A102780 [620-08-6]

4-Methoxypyridine

Similarity: 0.82

Chemical Structure| 2176-45-6

A119484 [2176-45-6]

3-Phenoxypyridine

Similarity: 0.82

Chemical Structure| 18677-48-0

A220345 [18677-48-0]

3,5-Dimethoxypyridine

Similarity: 0.82

Chemical Structure| 109345-94-0

A136172 [109345-94-0]

5-Methoxypyridin-3-ol

Similarity: 0.80

Related Parent Nucleus of
[ 109613-93-6 ]

Pyridines

Chemical Structure| 10182-48-6

A568217 [10182-48-6]

Pyridine-3,4-diol

Similarity: 0.89

Chemical Structure| 7295-76-3

A274716 [7295-76-3]

3-Methoxypyridine

Similarity: 0.84

Chemical Structure| 620-08-6

A102780 [620-08-6]

4-Methoxypyridine

Similarity: 0.82

Chemical Structure| 2176-45-6

A119484 [2176-45-6]

3-Phenoxypyridine

Similarity: 0.82

Chemical Structure| 18677-48-0

A220345 [18677-48-0]

3,5-Dimethoxypyridine

Similarity: 0.82